Several studies have established a link between microbial metabolite dysregulation and the progression of diseases such as obesity and hypertension. However, the role of the gut microbiome and its metabolism in chronic kidney disease (CKD) remains largely unknown. A new study demonstrates that reductions in the levels of Lactobacillus johnsonii and microbial-derived indole-3-aldehyde (IAld) largely contribute to CKD progression in rats. The investigators notably showed that L. johnsonii abundance was reduced in rats with adenine-induced CKD, while L. johnsonii supplementation ameliorated renal fibrosis in the animals. Similarly, the team showed that IAld level was decreased in the serum of rats in which CKD was induced using unilateral ureteral obstruction and 5/6 nephrectomy, while IAld treatment dampened kidney lesion. The results also suggest that IAld protects against renal injury by improving intestinal epithelial barrier functions and suppressing aryl hydrocarbon receptor (AHR) signaling pathway, offering new potential pathways for the treatment of CKD.

Original reference: Miao, H. et al. Signal Transduct. Target Ther. 9, 195 (2024)

多项研究已经确定微生物代谢失调与肥胖和高血压等疾病的进展之间存在联系。然而，肠道微生物组及其代谢在慢性肾病（CKD）中的作用仍然很大程度上未知。一项新的研究表明，约氏乳杆菌和微生物来源的吲哚-3-醛 (IAld) 水平的降低很大程度上促进了大鼠 CKD 的进展。研究人员特别表明，在腺嘌呤诱导的 CKD 大鼠中，约氏乳杆菌丰度降低，而补充约氏乳杆菌可改善动物的肾纤维化。同样，研究小组发现，使用单侧输尿管梗阻和 5/6 肾切除术诱发 CKD 的大鼠血清中 IAld 水平降低，而 IAld 治疗可抑制肾脏病变。研究结果还表明，IAld 通过改善肠上皮屏障功能和抑制芳烃受体（AHR）信号通路来预防肾损伤，为 CKD 的治疗提供新的潜在途径。

原文参考： Miao, H. et al .信号转导器。目标治疗师。 9 , 195 (2024)